Brain

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Retrieved on: 
Tuesday, April 23, 2024
Pain, FDA, Brain, Cancer, Food, Prognosis, Survival, Breast, Research, FABP5, Transport, Dicarboxylic acid, IND, Drug discovery, Patient, Metabolism, Neuropathic pain, FABP, FABP7, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry

Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

Key Points: 
  • Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.
  • Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
  • In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).
  • For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Retrieved on: 
Monday, April 22, 2024
Brain, Euronext Growth, Pericyte, IDUA, Traffic barrier, Integrin alpha M, HSPC, Mouse, CD4, Myelocyte, CD20, Cell, Intron, DNA, Therapy, Patient, Gene, Society, BBB, DSM-IV codes, Mucopolysaccharidosis, Vaccine

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first data exploring novel TALEN® editing processes in hematopoietic stem and progenitor cells (HSPCs) at the American Society of Gene and Cell Therapy (ASGCT) being held on May 7-11, 2024.

Key Points: 
  • “These two posters showcase the potential and versatility of the TALEN® technology to promote efficient gene insertion in HSPCs.
  • Cellectis has developed a TALEN® mediated promoter-less intron editing technology that enables the expression of a therapeutic transgene exclusively by monocyte derived from edited HSPCs.
  • This novel editing approach is an important addition to the HSPC gene editing toolbox that might unlock new strategies for the treatment of metabolic and neurological diseases.
  • Cellectis has developed and optimized a novel gene editing process, leveraging the TALEN® technology and circular single strand DNA template delivery, enabling highly efficient gene insertion in HSPCs.

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

Retrieved on: 
Monday, April 22, 2024
Plus Therapeutics, PSTV, CNS, Brain, Central nervous system, Therapy, Cancer, Pharmaceutical industry

AUSTIN, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer.

Key Points: 
  • Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization
    AUSTIN, Texas, April 22, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).
  • The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer.
  • “This recent award further extends our current cash runway in the second half of 2025, while supporting the 2024 expansion of our clinical development activities,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • “In 2023, the Company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024.”

Ibogaine By David Dardashti Offers New Treatment Procedure In Dedication Of Autism Awareness Month

Retrieved on: 
Sunday, April 21, 2024
Brain, Diagnosis, Neurochemistry, Autism spectrum, Spectrum, Anxiety, Asperger syndrome, Depression, Emotion, Linux

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- To commemorate Autism Awareness Month, Ibogaine By David Dardashti is reintroducing its autogenic self-creation therapy with ibogaine treatment for the autistic community.

Key Points: 
  • MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- To commemorate Autism Awareness Month, Ibogaine By David Dardashti is reintroducing its autogenic self-creation therapy with ibogaine treatment for the autistic community.
  • At his high school years, Gavriel Dardashti, the founder of Ibogaine By David Dardashti, was diagnosed with Aspergers.
  • He has pioneered the development of the autogenic self-creation therapy that is incorporated with ibogaine treatment for autism.
  • Ibogaine By David Dardashti invites those suffering from autism to seek out its treatment procedure and see how it can benefit their condition.

Lt. Gov. Dan Patrick tours $100 million Rio Grande Valley hospital: ‘An answer to prayer’

Retrieved on: 
Saturday, April 20, 2024
Brain, Hope, Travel, Robert Coronado, Bed, PHACE syndrome, Heart, Pediatrics, Patient, Physician, Child, Nursing

Dan Patrick visited South Texas on Saturday to tour Driscoll Children’s Hospital Rio Grande Valley.

Key Points: 
  • Dan Patrick visited South Texas on Saturday to tour Driscoll Children’s Hospital Rio Grande Valley.
  • Dan Patrick said, referring to the long drive patients in the Valley had to make to receive care at Driscoll Children's Hospital Corpus Christi, the nearest specialty acute care hospital for kids.
  • “The opening of this hospital will be instrumental in improving access to pediatric specialty care for families in the Rio Grande Valley.
  • Driscoll Children’s Hospital Rio Grande Valley, and the many pediatric subspecialists that will work in it, represent an entirely new level of services previously unavailable close to home,” said Matt Wolthoff, president of Driscoll Children's Hospital Rio Grande Valley.

Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Friday, April 19, 2024
Brain

(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”)

Key Points: 
  • (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”)
    Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its audited preliminary results for the year ended 31 December 2023.

 New Study Reveals Potential Treatment for Neurological Lyme Disease

Retrieved on: 
Friday, April 19, 2024
FDA, Brain, FGFR, Cancer, Inflammation, DSM-IV codes, Cell death, Bacteria, Apoptosis, FGFR3, FGFR2, Doctor of Philosophy, Research, Pathology, Borrelia burgdorferi, Sleep, Therapy, Nervous system, Patient, Lyme disease, Neuroborreliosis, Peripheral nervous system, Memory, Central nervous system, FGFR1, Frontiers, Knowledge, Infection, Pharmaceutical industry

PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing that fibroblast growth factor receptor (FGFR) inhibitors may be appropriate as anti-inflammatory supplementary treatment for neurological Lyme disease, for which there are no universally effective treatments.

Key Points: 
  • PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing that fibroblast growth factor receptor (FGFR) inhibitors may be appropriate as anti-inflammatory supplementary treatment for neurological Lyme disease, for which there are no universally effective treatments.
  • “Our research shows a potential connection between neurological Lyme disease and several other neurological conditions, and this common pathway may explain why Lyme can be confused with many other conditions.
  • “Lyme neuroborreliosis, or neurological Lyme, causes the most disabling symptoms in Lyme disease, yet there has been relatively little study of the disease mechanisms caused by the infection.
  • There has long been a question about whether the persistent neurological symptoms of Lyme disease are caused by live bacteria or bacterial remnants.

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Retrieved on: 
Thursday, April 18, 2024
Brain, L-DOPA, Therapy, Patient, Safety, Pharmaceutical industry

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without troublesome dyskinesia compared to those treated with LD and placebo (1.7 hours vs. 0.6 hours, p

Key Points: 
  • The TEMPO-3 trial evaluated the efficacy, safety and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults.
  • A statistically significant reduction in “off” time, the key secondary endpoint, was also observed for the tavapadon treatment arm.
  • The safety profile observed in the TEMPO-3 trial was consistent with prior clinical trials of tavapadon.
  • Topline results from the Phase 3 monotherapy trials for tavapadon, TEMPO-1 and TEMPO-2, are expected in the second half of 2024.

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Retrieved on: 
Thursday, April 18, 2024
RVV, FDA, Brain, COVID, SARS-CoV-2, Blood, Infection, Research, Therapy, Classification, Treatment, Fatigue, Revive, Arrhythmia, Diagnosis, Lawson Health Research Institute, Biomarker, Chest pain, COVID-19

The meeting date assigned by the FDA is June 7, 2024.

Key Points: 
  • The meeting date assigned by the FDA is June 7, 2024.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the Product as a potential blood biomarker diagnostic that characterizes long COVID.
  • Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
  • The Company entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to the intellectual property of novel blood biomarkers that characterize long COVID.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.